Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory Dermatoses

Anna Drosou, Robert Kirsner, Esperanza Welsh, Tory P. Sullivan, Francisco A. Kerdel

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Background: Infliximab is a monoclonal antibody against tumor necrosis factor alpha currently approved by the U.S. FDA for the treatment of Crohn's disease and rheumatoid arthritis. Recently, a controlled trial reported its effectiveness for psoriasis. Objective: The object of our study was to evaluate the efficacy and safety of infliximab for inflammatory or autoimmune cutaneous disorders. Methods: A retrospective chart review was performed for patients who received infliximab at the University of Miami, Cedars Medical Center. Results: Patients with various disease, including panniculitis, pityriasis rubra pilaris, eosinophilic fasciitis, discoid lupus erythematosus, and necrobiosis lipoidica diabeticorum, received infliximab infusion at a dose of 5 mg/kg. All patients had refractory disease or adverse effects to previous therapy, which included cyclosporine, systemic steroids, azathioprin, clofazimine, mycophenolate mofetil, acitretin, UVB, and thalidomide. Six out of the seven patients improved after treatment. Conclusions: Infliximab was well tolerated in most patients and the majority benefited from the use of infliximab.

Original languageEnglish
Pages (from-to)382-386
Number of pages5
JournalJournal of Cutaneous Medicine and Surgery
Volume7
Issue number5
DOIs
StatePublished - Sep 1 2003

Fingerprint

Skin Diseases
Necrosis
Antibodies
Neoplasms
Pityriasis Rubra Pilaris
Necrobiosis Lipoidica
Acitretin
Clofazimine
Discoid Lupus Erythematosus
Mycophenolic Acid
Panniculitis
Thalidomide
Psoriasis
Crohn Disease
Cyclosporine
Infliximab
Rheumatoid Arthritis
Therapeutics
Tumor Necrosis Factor-alpha
Steroids

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory Dermatoses. / Drosou, Anna; Kirsner, Robert; Welsh, Esperanza; Sullivan, Tory P.; Kerdel, Francisco A.

In: Journal of Cutaneous Medicine and Surgery, Vol. 7, No. 5, 01.09.2003, p. 382-386.

Research output: Contribution to journalArticle

Drosou, Anna ; Kirsner, Robert ; Welsh, Esperanza ; Sullivan, Tory P. ; Kerdel, Francisco A. / Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory Dermatoses. In: Journal of Cutaneous Medicine and Surgery. 2003 ; Vol. 7, No. 5. pp. 382-386.
@article{52793e16b41942db8740fad6e9f74150,
title = "Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory Dermatoses",
abstract = "Background: Infliximab is a monoclonal antibody against tumor necrosis factor alpha currently approved by the U.S. FDA for the treatment of Crohn's disease and rheumatoid arthritis. Recently, a controlled trial reported its effectiveness for psoriasis. Objective: The object of our study was to evaluate the efficacy and safety of infliximab for inflammatory or autoimmune cutaneous disorders. Methods: A retrospective chart review was performed for patients who received infliximab at the University of Miami, Cedars Medical Center. Results: Patients with various disease, including panniculitis, pityriasis rubra pilaris, eosinophilic fasciitis, discoid lupus erythematosus, and necrobiosis lipoidica diabeticorum, received infliximab infusion at a dose of 5 mg/kg. All patients had refractory disease or adverse effects to previous therapy, which included cyclosporine, systemic steroids, azathioprin, clofazimine, mycophenolate mofetil, acitretin, UVB, and thalidomide. Six out of the seven patients improved after treatment. Conclusions: Infliximab was well tolerated in most patients and the majority benefited from the use of infliximab.",
author = "Anna Drosou and Robert Kirsner and Esperanza Welsh and Sullivan, {Tory P.} and Kerdel, {Francisco A.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1007/s10227-002-0134-1",
language = "English",
volume = "7",
pages = "382--386",
journal = "Journal of Cutaneous Medicine and Surgery",
issn = "1203-4754",
publisher = "Decker Publishing",
number = "5",

}

TY - JOUR

T1 - Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory Dermatoses

AU - Drosou, Anna

AU - Kirsner, Robert

AU - Welsh, Esperanza

AU - Sullivan, Tory P.

AU - Kerdel, Francisco A.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Background: Infliximab is a monoclonal antibody against tumor necrosis factor alpha currently approved by the U.S. FDA for the treatment of Crohn's disease and rheumatoid arthritis. Recently, a controlled trial reported its effectiveness for psoriasis. Objective: The object of our study was to evaluate the efficacy and safety of infliximab for inflammatory or autoimmune cutaneous disorders. Methods: A retrospective chart review was performed for patients who received infliximab at the University of Miami, Cedars Medical Center. Results: Patients with various disease, including panniculitis, pityriasis rubra pilaris, eosinophilic fasciitis, discoid lupus erythematosus, and necrobiosis lipoidica diabeticorum, received infliximab infusion at a dose of 5 mg/kg. All patients had refractory disease or adverse effects to previous therapy, which included cyclosporine, systemic steroids, azathioprin, clofazimine, mycophenolate mofetil, acitretin, UVB, and thalidomide. Six out of the seven patients improved after treatment. Conclusions: Infliximab was well tolerated in most patients and the majority benefited from the use of infliximab.

AB - Background: Infliximab is a monoclonal antibody against tumor necrosis factor alpha currently approved by the U.S. FDA for the treatment of Crohn's disease and rheumatoid arthritis. Recently, a controlled trial reported its effectiveness for psoriasis. Objective: The object of our study was to evaluate the efficacy and safety of infliximab for inflammatory or autoimmune cutaneous disorders. Methods: A retrospective chart review was performed for patients who received infliximab at the University of Miami, Cedars Medical Center. Results: Patients with various disease, including panniculitis, pityriasis rubra pilaris, eosinophilic fasciitis, discoid lupus erythematosus, and necrobiosis lipoidica diabeticorum, received infliximab infusion at a dose of 5 mg/kg. All patients had refractory disease or adverse effects to previous therapy, which included cyclosporine, systemic steroids, azathioprin, clofazimine, mycophenolate mofetil, acitretin, UVB, and thalidomide. Six out of the seven patients improved after treatment. Conclusions: Infliximab was well tolerated in most patients and the majority benefited from the use of infliximab.

UR - http://www.scopus.com/inward/record.url?scp=0344629146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344629146&partnerID=8YFLogxK

U2 - 10.1007/s10227-002-0134-1

DO - 10.1007/s10227-002-0134-1

M3 - Article

VL - 7

SP - 382

EP - 386

JO - Journal of Cutaneous Medicine and Surgery

JF - Journal of Cutaneous Medicine and Surgery

SN - 1203-4754

IS - 5

ER -